Welcome to the McGill International Tuberculosis Centre

A PAHO/WHO Collaborating Centre for Tuberculosis Research

Read more

With over 10 million new TB cases, and 1.6 million deaths, TB is the leading infectious killer of humanity. In Canada, the TB rate among the Inuit is about 283 times higher than that of the Canadian-born non-Indigenous. 

TB Centre Goal

Starting Oct 15th 2020, Dr Madhukar Pai hands over TB Centre Directorship to Dr Dick Menzies. Under his leadership, the TB Centre made significant strides in bringing much needed attention to TB, locally and internationally. We thank Dr Pai for his outstanding leadership as we welcome Dr Menzies.

Our centre brings together over 20 investigators with expertise spanning epidemiology, policy setting, economic analyses, implementation research, meta-analyses, qualitative research to basic science in microbiology, host genetics and immune response.

Our investigators


Our work is done both as an academic centre and with a number of collaborating groups around the world. Find out why our Centre is a world leader in the interdisciplinary study of TB and how we work together to unravel the many mysteries of this recalcitrant disease.

Our Activities

Diagnosis and treatment of TB is sub-optimal in many settings. The McGill TB Center is working to improve quality of care for TB patients.

Projects and partnerships

A webinar series on epidemiology for health communication for Journalists


Watch the YouTube Videos

Home Page

Dr. Maziar Divangahi elected Member of the RSC

The TB Centre congratulates Maziar Divangahi for being elected member of the Royal Society of Canada. He is among 50 new members of the College of New Scholars, Artists and Scientists in Canada.

Quality of TB Care eBook

This free eBook is a compilation of a series on Quality of TB Care, published in the Journal of Clinical Tuberculosis & Other Mycobacterial Diseases.

TB Centre Activities

Summer courses, Research Day and monthly Seminars are useful for researchers, implementers and policy-makers in Global Health

In the Media

No doubt, COVID-19 will adversely affect all routine health services everywhere. But TB services is among the biggest casualties. 

YouTube Channel

Our webinar series on Epidemiology for Health Journalists is a useful tool for communicating scientific publications. 


TB Center in the Media

COVID-19 Coronavirus And Tuberculosis: We Need A Damage Control Plan


"No doubt, COVID-19 will adversely affect all routine health services everywhere. But TB services is might be one of the biggest casualties. ".

Read the Forbes article here

AIDS, TB And Malaria: Coronavirus Threatens The Endgame

"It is clear that the coronavirus pandemic has just made it incredibly difficult to script an endgame for the “Big Three” killer epidemics".
Read more

Recent media appearances


Click here for more


Impact of COVID-19 on TB

Briefing note | Global TB Caucus and the McGill International TB Center

 TB kills 4000 people each day, and 1.5 million people each year. An estimated 10 million people fell ill in 2018, of which nearly half a million developed drug-resistant TB (DR-TB). It is the leading killer of people living with HIV/ AIDS today.

 TB and COVID-19 are both airborne infectious diseases and have considerable social and economical impact. In the first quarter of 2020, COVID-19 has infected more than 700,000 people in 193 countries, and this number is rising at an alarming rate.

Anticipated impact of COVID-19 on people affected by TB and TB survivors

TB services will be impacted at various levels as resources are diverted to COVID-19 and the epidemic ramps up. So, high TB burden countries must do everything they can to protect people in treatment for TB and survivors from COVID-19 exposure. 

Impact on the health care and TB infrastructure

COVID-19 will divert healthcare workforce and resources away from routine TB services. There may be a reduction in the number of health workers because of illness and self-isolation. 

Impact on global TB resources

COVID-19 is already depleting and disrupting the global supply chain for all drugs, including TB medicines, and other products (e.g. N95 respirators).

In the longer term, countries may cut expenditure on TB, because of the massive economic loss due to COVID-19.

For more information on how to mitigate these impactsEnglishFrenchSpanish, Indonesian, Portuguese and Russian








Back to top